Comparison of the effect and mechanism of transplantation of bone marrow mesenchymal stem cells and cardiac sca1-positive stem cells on myocardial infarction
SUN Qi, SHAN Wei
Chinese Journal of Clinical Anatomy ›› 2019, Vol. 37 ›› Issue (2) : 160-164.
Comparison of the effect and mechanism of transplantation of bone marrow mesenchymal stem cells and cardiac sca1-positive stem cells on myocardial infarction
Objective To investigate the therapeutic effect of bone marrow mesenchymal stem cell (MSCs) and cardiac-derived Sca1 positive stem cell on acute myocardial infarction model in mice. Methods Bone marrow mesenchymal stem cells were isolated from the femur bone marrow of adult C57BL/C mice, and Sca1 positive stem cells were harvested from the heart by flow cytometry. Twenty-four male C57BL/C mice were divided into four groups: sham group, control group, bone marrow MSCs treated group and Sca1 positive cells treated group. After anesthesia, the mouse thorax was opened and the left anterior descending coronary artery (LAD) was ligated to establish the acute myocardial infarction model. After successful LAD ligation, cells were injected into the infarcted myocardium. Four weeks later, cardiac ultrasound was used to observe heart function: the left ventricular ejection fraction (LVEF) and left ventricular (LV) end dilated volume. In addition, quantitative PCR was used to evaluate the RNA expression of VEGFa and VEGFb in cultured cells. Results The cultured bone marrow MSCs adhered to the dish and showed a spindle shape. The positive rate of Sca1 positive stem cells was about 18 %, and they also adhered to the dish while showed a short shuttle-like shape. Compared with Sca1positive stem cell therapy, MSCs treatment increased the survival rate of mice after myocardial infarction. After 4 weeks of cell transplantation therapy, the LVEF of the bone marrow-derived MSCs treatment group was significantly higher than that of the cardiac-derived Sca1 positive stem cell treatment group, while the LV end dilated volume was lower. The expression of VEGFa and VEGFb was significantly higher in bone-derived MSCs. Conclusion Both bone marrow-derived MSCs and Cardiac-derived Sca1positive stem cells are beneficial to the improvement of cardiac function after infarction, and bone marrow-derived MSCs are superior in improving LVEF and inhibiting enlargement of left ventricular after myocardial infarction in mice, which may be caused by the high expression of VEGF in bone marrow derived MSC.
Bone marrow mesenchymal stem cell / Sca1; / Myocardial infarction; / Cell transplantation; / VEGF
[1] Wang W, Hu SS, Kong LZ, et al. Summary of report on cardiovascular diseases in China, 2012[J]. Biomed Environ Sci, 2014, 27(7): 552-558.
[2] Aronow WS. Treatment after myocardial infarction[J]. Compr Ther, 2007, 33(1): 39-47.
[3] Rossini A, Frati C, Lagrasta C, et al. Human cardiac and bone marrow stromal cells exhibit distinctive properties related to their origin[J]. Cardiovasc Res, 2011, 89(3): 650-660.
[4] Terzic A, Behfar A. Stem cell therapy for heart failure: ensuring regenerative proficiency[J]. Trends Cardiovasc Med, 2016, 26(5): 395-404.
[5] Burlacu A. Tracking the mesenchymal stem cell fate after transplantation into the infarcted myocardium[J]. Curr Stem Cell Res Ther, 2013, 8(4): 284-291.
[6] Uchida S, De Gaspari P, Kostin S, et al. Sca1-derived cells are a source of myocardial renewal in the murine adult heart[J]. Stem Cell Reports, 2013, 1(5): 397-410.
[7] 张稷，吴家林, 范志海, 等. 体外诱导骨髓间充质干细胞向心肌细胞分化的实验研究[J]. 中国临床解剖学杂志, 2007, 25(1): 68-73.
[8] Chang Y, Li C, Jia Y, et al. CD90+ cardiac fibroblasts reduce fibrosis of acute myocardial injury in rats[J]. Int J Biochem Cell Biol, 2018, 96: 20-28.
[9] Lee N, Thorne T, Losordo DW, et al. Repair of ischemic heart disease with novel bone marrow-derived multipotent stem cells[J]. Cell Cycle, 2005, 4(7): 861-864.
[10]Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluripotency of mesenchymal stem cells derived from adult marrow[J]. Nature, 2002, 418(6893): 41-49.
[11]Russo V, Young S, Hamilton A, et al. Mesenchymal stem cell delivery strategies to promote cardiac regeneration following ischemic injury[J]. Biomaterials, 2014, 35(13): 3956-3974.
[12]Duran JM, Makarewich CA, Sharp TE, et al. Bone-derived stem cells repair the heart after myocardial infarction through transdifferentiation and paracrine signaling mechanisms[J]. Circ Res, 2013, 113(5): 539-552.
[13]Kocher AA, Schuster MD, Szabolcs MJ, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function[J]. Nat Med, 2001, 7(4): 430-436.
[14] Zisa D, Shabbir A, Suzuki G, et al. Vascular endothelial growth factor (VEGF) as a key therapeutic trophic factor in bone marrow mesenchymal stem cell-mediated cardiac repair[J]. Biochem Biophys Res Commun, 2009, 390(3): 834-838.
[15] Tao Z, Chen B, Tan X, et al. Coexpression of VEGF and angiopoietin-1 promotes angiogenesis and cardiomyocyte proliferation reduces apoptosis in porcine myocardial infarction (MI) heart[J]. Proc Natl Acad Sci U S A, 2011, 108(5): 2064-2069.
[16]Tang JM, Wang JN, Zhang L, et al. VEGF/SDF-1 promotes cardiac stem cell mobilization and myocardial repair in the infarcted heart[J]. Cardiovasc Res, 2011, 91(3): 402-411.
[17] Chien KR, Frisén J, Fritsche-Danielson R, et al. Regenerating the field of cardiovascular cell therapy[J]. Nat Biotechnol, 2019, 37(3): 232-237.
/
| 〈 |
|
〉 |
